NIH chief Dr. Francis Collins rejected criticism from the Office of Human Research Protections over a study that evaluated dosing of oxygen for premature infants. At the time the study began, data did not indicate outcomes would be worse at either end of the studied spectrum of oxygen dosing, Collins and two other NIH officials write in the New England Journal of Medicine. The controversy "has alarmed some of the parents of infants who were in the study, confused the biomedical research community, and befuddled [Institutional Review Boards]," they wrote.
NIH's Collins defends study of oxygen dosing in premature infants
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|